

Index

a

- acivicin 150
- actin 262
- adhesins 267
- alanyl-tRNA synthetase (AlaRS) 445
- albitiazolium 174
- aldolase 261
- alkaloids 84
- alveolins 266
- aminoacyl t-RNA synthetases
 - alanyl-tRNA synthetase (AlaRS) 445
 - classes 444
 - computational and bioinformatics tools 445
 - isoleucyl-tRNA synthetase (IleRS) 446
 - lysyl-tRNA synthetase (LysRS) 447
 - methionyl-tRNA synthetase (MetRS) 446
 - prolyl-tRNA synthetase (ProRS) 449
 - requirement 445
 - spatial distribution of *P. falciparum* 443, 444
 - threonyl-tRNA synthetase (ThrRS) 446
 - two step aminoacylation reaction 443
- 4-aminoquinolines 277
- anaerobic protozoan parasites 66
- anti-apicomplexan compounds 333
- antifolates and antimonials 12
- anti-malarial drug mechanisms 331
- anti-malarials, drug discovery, *see*
 - aminoacyl-tRNA synthetases 442
- apicomplexa 457
 - autophagy conservation 217
 - autophagy protein function 218
 - characteristics 216
 - *Cryptosporidium parvum* 216
 - diseases 196
 - features 196
 - FK506 199

- immunophilins 196
- mathematical modelling
 - – constraint based modeling 470
 - – data mining and machine learning studies 468
 - – kinetic pathways modeling 471
 - – omics data analysis 462
 - – comparative genomics 460
 - – fluxomics 462
 - – metabolomics 461
 - – proteomics 460, 462
 - – transcriptomics 460, 462
 - – *PfFKBP35* 199
 - – plasmodial Atg8-conjugation pathway 220
 - – *Plasmodium knowlesi*
 - – glycerophospholipid model training and parameter estimation 475
 - – ODE model vs.FBA 476
 - – phospholipid synthetic pathways model 474
 - – sensitivity analysis and rate-limiting steps 477
 - – *in silico* knock-out experiments 477
 - – *TgCYP18* 200
 - – *TgFCBP57* 201
 - – *Toxoplasma gondii* 216
- apicomplexan parasites
 - anti-malarial drug mechanisms 331
 - economic and public health 255
 - glideosome 260
 - invasion machinery 259
 - malaria 256
 - *Plasmodium* drug-resistance mechanisms 333
 - phylogenetic relation, human and livestock pathogens 256

- apicoplast metabolism
 - DMAP 387
 - electron shuttle system 387
 - IPP biosynthesis 386
 - phosphate transporters 384
 - plant plastid PDC E2 386
 - plastid-like organelle 383
 - pyruvate kinase 385
 - targeted proteins 383
- artemisinin 96, 278
- aspartate carbamoyltransferase (ACT) 151
- autophagy
 - apicomplexan protein functions 218
 - cellular homeostasis 213
 - conservation in apicomplexa 217
 - functions 214
 - pexophagy 243
 - ubiquitin-like protein 214
 - xenophagy 214
- b**
 - β -tocopherylhydroquinone 58
 - brown alga *Sargassum heterophyllum* 58
- c**
 - CAD-like complex 149
 - carbamoyl-phosphate synthetase II (CPSII) 150
 - centromeres 405
 - Chagas disease 76, 330
 - chloroquine 11, 276, 277
 - choline kinase (CK) 175
 - choline phosphotransferase (CPT) 182
 - chromatin remodeling enzymes 425
 - chromosomes, *P.falciparum* 430
 - cladosporin 448
 - constraint based modeling 470, 488, 502, 518
 - Crassulacean acid metabolism (CAM) 377
 - cruzain
 - host cell invasion 123, 124
 - identification and validation 121
 - immunomodulator 124
 - metacyclogenesis 123
 - TGF- β activation 124
 - Ctenocephalides felis* 105
 - cyclophilins 204
 - cysteine-loop ligand-gated chloride channels (CysLGCCs) 107, 114
 - cysteine peptidases
 - anti-trypanosomal inhibitors 129
 - hydrazones 134
 - nitriles 134
 - non-peptidic inhibitors 135
 - potent inhibitors 129
 - thiosemicarbazones 133
 - *Trypanosoma brucei* 126
 - *Trypanosoma cruzi* 121
 - vinyl and allyl sulfones 131
 - cytidine triphosphate synthetase (CTPS) 154, 156
 - cytidylyltransferases 178
 - cytosolic glucose metabolism 376
 - d**
 - deoxyuridine triphosphate
 - nucleotidohydrolase (dUTPase) 154, 162
 - Dermatocentor variabilis* 105
 - δ -tocopherylquinone 58
 - difluoromethylornithine (DFMO) 9
 - dihydrofolate reductase-thymidylate synthase (DHFR-TS) 154, 159
 - dihydroorotate (DHO) 151
 - dihydroorotate dehydrogenase (DHODH) 152
 - flavin mononucleotide (FMN) 152
 - *Helicobacter pylori* 152
 - *Trypanosoma* 152
 - dimerization inhibitors 159
 - drug
 - activation 10
 - eflorenithine, *see* difluoromethylornithine (DFMO) 9
 - macromolecular synthesis 8
 - melarsoprol and diamidines 9
 - metabolomics 23
 - morphology 7
 - proteins and proteomes, *see* proteome 18
 - structures 8
 - target deconvolution process 6
 - validation 25
 - drug-resistant lines
 - microarrays 13
 - mRNA levels
 - - candidate gene 15
 - - microarrays and sequencing 15
 - whole genome sequencing 13
 - e**
 - ectoparasites
 - isoxazoline, *see* isoxazoline 108
 - ligand-gated chloride channels 106, 110
 - mode of action 107
 - prevention of arthropod 105
 - elongation factor 2 (eEF2) 281
 - Entamoeba histolytica* 66
 - endo-metabolomics 314
 - epigenetics
 - chromatin 403

- definition 402
- machinery 402
- memory 402
- regulation of gene expression in *P.falciparum* 409
- antigenic variation 410
- gametocyte conversion 412
- ethanolamine kinase (EK) 175
- euchromatin 407, 408
- exo-metabolomics 311

f

- FK506- and cyclosporin-binding protein (FCBP) 205
- FK506-binding proteins (FKBP) 202
- flavonoids 92
- flux balance analysis 470, 489, 497, 501, 517
 - application software 504
 - druggability of protein target 504

g

- γ -aminobutyric-acid-gated chloride channels (GABACls) 107, 111
- GAPMs 266
- genome-scale models 517
- genome-scale reconstruction
 - automated metabolic network reconstruction 494
 - databases 498
 - INPARANOID 498
 - manually curated model 498
 - manual refinement 494
 - Pathway Tools 497
 - SEED server 497
 - standardization and model formats 495
- Giardia lamblia* 66
- glideosome 258, 259
 - components 261, 267
 - conservation in apicomplexan 260
- glideosome associated proteins (GAP) 265
- glutamate-gated chloride channels (GluCls) 107, 112

- glycolysis model, *T. brucei* 521
- glycosomal matrix proteins 238
- glycosomes
 - autophagy and pexophagy 243
 - biogenesis 236
 - degradation 245
 - enzymes 232, 234
 - metabolism during life cycle 234
 - peroxisomes 232
 - protein induced biogenesis 245
 - trypanosomatid parasites 231, 237

h

- halofuginone 448
- helminths 67
- histones
 - acetylation 429
 - methylation 430
 - post-translational modification (PTM) 428
- human African trypanosomiasis (HAT) 76, 329
- hydrazones 133

i

- imidazopyrazines 279
- immunophilins
 - in apicomplexa, *see apicomplexa* 196
 - cis-trans isomerization 193
 - chemical structures of ligands 194, 201
 - cyclophilins 204
 - FCBP 205
 - FKBP 202
 - genes 195
 - history 194
 - HIV infections 196
 - in steroid receptors 195
- inner membrane complex (IMC) 265
- isoleucyl-tRNA synthetase (IleRS) 446
- isotopes 307
- isotopologues 307
- isotopomers 307
- isoxazoline
 - binding site 113
 - derivatives 109, 115
 - GABACls and GluCls 108
 - mode of action 112
 - selectivity and safety 114

k

- Kennedy pathways 172, 183, 349, 474
- Kinetoplastida 60
- kinetoplastid parasites
 - Chagas disease 330
 - human African trypanosomiasis 329
 - leishmaniasis 330

l

- Leishmania* major 490
- Leishmania* spp. 60, 346
- leishmaniasis 76
- lipid metabolism
 - composition 355
 - electrospray ionisation mass spectrometry (ESI-MS) 356
 - gas chromatography mass spectrometry (GC-MS) 358

- lipid metabolism (*contd.*)
 - nuclear magnetic resonance (NMR) 359
 - parasites nutrient requirements 344
- long non-coding RNAs (lncRNAs) 433
- lysyl-tRNA synthetase (LysRS) 447, 448

- m**
- macroautophagy, *see* autophagy 213
- malaria 256
 - artemisinin combination therapy 278
 - caused by *Plasmodium* 275
 - life cycle of, parasite 258
 - malaria parasites, epigenetic regulations in *P. falciparum* 403
 - melarsoprol 9
- metabolic control analysis (MCA) 477, 526
- metabolic fingerprinting and footprinting 299
- metabolic model simulation
 - Acorn 504
 - COBRA Toolbox 503, 504
 - flux balance analysis 501, 505
 - OptFlux 504
 - SurreyFBA 504
- metabolomics 23
 - in apicomplexan parasites 331
 - – anti-apicomplexan compounds 333
 - – anti-malarial drug mechanisms 331
 - – *Plasmodium* drug-resistance mechanisms 333
 - application of 308
 - in drug discovery 323
 - endo-metabolomics 314
 - exo-metabolomics 311
 - isotopes and isotopic profiling 307
 - in kinetoplastid parasites
 - – American trypanosomiasis, *see Chagas disease* 330
 - – human African trypanosomiasis 329
 - – leishmaniasis 330
 - mass spectrometry 305, 306
 - mechanism of action, protozoan parasites 325
 - methodology
 - – data analysis 328
 - – design 324
 - – liquid chromatography 327
 - – mass spectrometry 326
 - – mechanism of action 324
 - – metabolite identification 328
 - – method validation 328
 - – reversed-phase chromatography 327
 - – sample preparation 326
 - – NMR 304
- principle 323
- redox balances and gluconeogenesis 314
- sample preparation 301
- sampling method, *T. brucei* 303
- succinate fermentation 311
- metacyclogenesis 123
- MetaTIGER 501
- methionyl-tRNA synthetase (MetRS) 446
- microalgae 69
- miltefosine 12
- mitochondrial electron transport 382
- mitochondrial metabolism
 - ATP in aerobic organisms 378
 - electron transport 382
 - genetic manipulation 381
 - glycolysis and TCA cycle 380
 - malate 380
 - metabolomics approaches 378
 - *Plasmodium* species 378
- MTIP/MLC1 264
- myosin A 263

- n**
- nitriles 134
- N-myristoyltransferase (NMT)
 - function 290
 - high-throughput approach 288
 - mechanism 282
 - NMT validation in malaria 290
 - piggy-back approach 286
 - proteins 281
 - specificity 284
 - structure 284
 - target for drug discovery 285
- nucleoskeleton proteins 431
- nucleosomes, *P. falciparum* 424

- p**
- parasite metabolism
 - artemisinin-combination therapy 516
 - detailed kinetic models
 - construction of kinetic models 519
 - enzyme activity 519
 - – glycolysis of BSF *T. brucei* 521
 - – *P. falciparum* trophozoite model 524
 - eflornithine 515
 - genome-scale models 517
 - glycolysis 516
 - intraerythrocyte stage of *Plasmodium* 514
 - kinetic models of *T. brucei* and *P. falciparum* 473, 528
 - metabolic control analysis (MCA) 477, 526
 - rapid cell death 515
 - *Trypanosoma brucei* 514

- peroxisomal membrane proteins (PMP) 236, 238
 pexophagy 243
 phenotypic screening and inhibitors 279
 phosphatidylethanolamine
 N-methyltransferase (PEMT) 185
 phosphatidyl-inositol-4 kinase (PI4K) 280
 phosphatidyl-inositol 3-phosphate kinase (PI3K) 214
 phosphoethanolamine methyltransferase (PMT) 183
 phospholipid metabolism
 – ajoene 351
 – albitiazolium 352
 – alkyllysophospholipid (ALP) 350
 – TC95 353
Plasmodium drug-resistance mechanisms 333
Plasmodium export element (PEXEL) 460
Plasmodium falciparum 42, 276, 458, 491
 – apicoplast metabolism 383
 – application of MCA 527
 – chromatin remodeling enzymes 425
 – chromosomes 430
 – centromeres 405
 – cytosolic glucose metabolism 376
 – differential network-based drug design 529
 – disease state 529
 – epigenetic regulation of gene expression 409
 – – antigenic variation 410
 – – gamete conversion 412
 – – euchromatin 407, 408
 – gene expression to metabolic models 528
 – genome 403
 – histone acetyl transferases (HAT) 429
 – histone deacetylases (HDACs) 429
 – histone lysine methyltransferases (HKMTs) 430
 – histone post-translational modification (PTM) 428
 – long non-coding RNAs (lncRNAs) 433
 – mechanisms of transcriptional regulation 426
 – mitochondrial metabolism 377
 – nucleoskeleton proteins 431
 – nucleosomes 424
 – post-transcription control 433
 – telomeres 407
 – transcription 421, 422
 – trophozoite model
 – – construction 524
 – – validation and use 525
Plasmodium parasites, NMT function 290
Plasmodium spp. 347, 348
 polyketides and peptides 93
 prolyl-tRNA synthetase (ProRS) 448, 449
 proteome
 – activity-based probes 21
 – affinity chromatography 19
 – display 23
 – isobaric tag for relative and absolute quantitation (iTRAQ) 19
 – label-free approaches 22
 – multidimensional protein identification technology 19
 – stable isotope labelling by amino acids in cell culture (SILAC) 19
 protozoan parasite metabolism
 – constraint-based modelling 488
 – genome-scale models 488
 – genome-scale reconstruction, *see* genome-scale reconstruction 494
 – *Leishmania major* 490
 – metabolic model simulation 501
 – *Plasmodium falciparum* 491
 – *Trypanosoma brucei* 492
 – *Trypanosoma cruzi* 493
 pyrimethamine 277
 pyrimidine metabolism
 – de novo biosynthesis 148, 149
 – pyrimidine salvage 153
 – UMP downstream enzymes 156
- q**
 quinine 11, 96
- r**
 reverse genetic screens
 – gain-of-function screens 16
 – loss-of-function screens 17
Rhipicephalus microplus 105
 ribonucleotide reductase (RNR) 154, 158
- s**
Simparica 115
 single exposure radical cure and prophylaxis (SERCaP) 442
 sleeping sickness, *see* human African trypanosomiasis (HAT) 329
 sterol metabolism
 – bisphosphonate 354
 – ergosterol 355
 – fosmidomycin 354
 – isoprenoids 353
 – pamidronate 355
 sulphadoxine 277

t

- telomeres 407
- terpenoids 88
- thiosemicarbazones 132
- threonyl-tRNA synthetase (ThrRS) 446
- thymidine kinase (TK) 154, 155
- Trypanosoma brucei* 60, 126, 233, 492
 - application of MCA 527
 - differential network-based drug design 529
 - disease state 529
 - gene expression to metabolic models 528
 - glycolysis model
 - – construction and updates 521
 - – validation and use 521
 - glycosome 298
 - kinetoplast 298
 - metabolism 298
 - metabolism through lifecycle stages 514

– metabolomics, *see* metabolomics 299

– sampling method, metabolome 303

– unconventional organisms 297

Trypanosoma cruzi 60, 121, 493

Trichomonas vaginalis 66

u

UMP synthase (UMPS) 152

uracil phosphoribosyltransferase (UPRT)
154, 155

v

vacuolar transport signal (VTS) 460

vinyl and allyl sulfones 131

w

Warburg effect 323

Wuchereria bancrofti 68